Navigation Links
For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission
Date:4/16/2009

Abbott/Eisai's Humira Will Earn Decision Resources' Clinical Gold Standard Status for Ulcerative Colitis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists identify a therapy's effect on induction of remission as the attribute that most influences their prescribing decisions in moderate to severe ulcerative colitis. Clinical data and the opinions of interviewed thought leaders indicate that corticosteroids have advantages in this attribute over Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade (infliximab), the sales-leading agent in the market.

The new report entitled Ulcerative Colitis: Opportunity Awaits Therapies That Treat Moderate to Severe Disease More Effectively Than Infliximab finds that a drug that maintains remission in a higher percentage of patients with moderate to severe ulcerative colitis than infliximab at one year would earn a 30 percent patient share in the United States and a 15 percent patient share in Europe, according to surveyed U.S. and European gastroenterologists.

In 2008, Decision Resources' proprietary clinical gold standard for ulcerative colitis was prednisone. Based on available data and expert opinion, Abbott/Eisai's Humira (adalimumab) will earn gold-standard status for ulcerative colitis in 2012, following its approval for the indication in 2011. Interviewed experts believe that adalimumab has potential to be superior in maintenance of remission when compared to infliximab.

"Although clinical trial data are limited, interviewed experts believe that adalimumab will be more effective than infliximab in the maintenance setting and that it offers superior safety and tolerability when compared with other drugs in the market, including infliximab," said Decision Resources Analyst Benjamin Guikema, Ph.D. "Adalimumab also has a reduced risk of major organ toxicity, giving it a significant advantage over all other currently available therapies."

About the Report

Ulcerative Colitis: Opportunity Awaits Therapies That Treat Moderate to Severe Disease More Effectively Than Infliximab is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                               Decision Resources, Inc.
    Christopher Comfort                              Elizabeth Marshall
    781-296-2597                                     781-296-2563
    ccomfort@dresources.com                          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New therapeutic targets in the treatment of ulcerative colitis
2. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
3. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
4. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
5. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
6. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
7. Study underway to find an alternative cure for Crohns disease and ulcerative colitis
8. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
9. Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis?
10. Companies Pay a High Price for Employees With Crohns Disease and Ulcerative Colitis, According to Study From Thomson Reuters
11. Identification of genetic markers for ulcerative colitis could lead to treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted by Canadian ... Forum held recently at the Annual Meeting in Los Angeles. The first annual art ... members and Annual Meeting attendees. , “Through art I hope to educate people ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, dentist in Agoura ... treatments. In the past, many necessary dental treatments could require multiple appointments to complete. ... shots and extra chair time. Not only could this be inconvenient, but it could ...
(Date:5/2/2016)... ... May 02, 2016 , ... This week Omega Institute, a premier nonprofit educational ... runs through October. Omega is offering a record 370 in-person workshops and new ... been such widespread interest in or need for the knowledge and skills we’ve been ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also ... as the kidneys, liver and pancreas. If not properly addressed, visceral fat can ... in Internal Medicine, Medical Oncology and Palliative Care, warns against the dangers of ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Pregnancy Awareness ... when trying to conceive. , “If you are ready to have a ... Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/28/2016)... , April 28, 2016   Click ... Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... signed a definitive agreement to acquire Valley Campus ... Pharmacy ("TNH"), a leading specialty pharmacy that provides ... Nuys, California . In 2015, TNH generated ...
(Date:4/28/2016)... , April 28, 2016  Marking its one ... breast and ovarian cancer risk test, Color ... 30 genes that highly impact the most common ... today, the Color Test analyzes hereditary cancer risks ... and uterine cancers. The Color Test is physician ...
Breaking Medicine Technology: